These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36566773)

  • 1. The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts.
    Westerhof I; de Hoog M; Ieven M; Lammens C; van Beek J; Rozhnova G; Eggink D; Euser S; Wildenbeest J; Duijts L; van Houten M; Goossens H; Giaquinto C; Bruijning-Verhagen P
    Int J Infect Dis; 2023 Mar; 128():140-147. PubMed ID: 36566773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 Periods.
    Marquez C; Kerkhoff AD; Schrom J; Rojas S; Black D; Mitchell A; Wang CY; Pilarowski G; Ribeiro S; Jones D; Payan J; Manganelli S; Rojas S; Lemus J; Jain V; Chamie G; Tulier-Laiwa V; Petersen M; DeRisi J; Havlir DV
    JAMA Netw Open; 2022 Oct; 5(10):e2235844. PubMed ID: 36215069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.
    Townsley H; Gahir J; Russell TW; Greenwood D; Carr EJ; Dyke M; Adams L; Miah M; Clayton B; Smith C; Miranda M; Mears HV; Bailey C; Black JRM; Fowler AS; Crawford M; Wilkinson K; Hutchinson M; Harvey R; O'Reilly N; Kelly G; Goldstone R; Beale R; Papineni P; Corrah T; Gilson R; Caidan S; Nicod J; Gamblin S; Kassiotis G; Libri V; Williams B; Gandhi S; Kucharski AJ; Swanton C; Bauer DLV; Wall EC
    PLoS One; 2024; 19(3):e0294897. PubMed ID: 38512960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.
    Nakakubo S; Kishida N; Okuda K; Kamada K; Iwama M; Suzuki M; Yokota I; Ito YM; Nasuhara Y; Boucher RC; Konno S
    Lancet Infect Dis; 2023 Nov; 23(11):1244-1256. PubMed ID: 37399831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022.
    Havers FP; Patel K; Whitaker M; Milucky J; Reingold A; Armistead I; Meek J; Anderson EJ; Weigel A; Reeg L; Seys S; Ropp SL; Spina N; Felsen CB; Moran NE; Sutton M; Talbot HK; George A; Taylor CA;
    MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(34):1085-1091. PubMed ID: 36006841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022.
    Taylor CA; Whitaker M; Anglin O; Milucky J; Patel K; Pham H; Chai SJ; Alden NB; Yousey-Hindes K; Anderson EJ; Teno K; Reeg L; Como-Sabetti K; Bleecker M; Barney G; Bennett NM; Billing LM; Sutton M; Talbot HK; McCaffrey K; Havers FP;
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(12):466-473. PubMed ID: 35324880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.
    Martínez-Baz I; Trobajo-Sanmartín C; Miqueleiz A; Casado I; Navascués A; Burgui C; Ezpeleta C; Castilla J; Guevara M; ;
    Euro Surveill; 2023 Feb; 28(5):. PubMed ID: 36729113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
    Wan J; Cazer CL; Clarkberg ME; Henderson SG; Lee SE; Meredith GR; Osman M; Shmoys DB; Frazier PI
    PLoS Med; 2023 Jan; 20(1):e1004153. PubMed ID: 36626376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of clinical characteristics of 362 vaccinated or unvaccinated patients infected by novel coronavirus Omicron variant].
    Feng Q; Wang Z; Yu H; Shi L; Xu L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 May; 34(5):459-464. PubMed ID: 35728844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term neuropsychiatric sequelae of Delta versus Omicron SARS-CoV-2 infection.
    Wee LE; Lim JT; Tay AT; Pang D; Dickens B; Chiew CJ; Ong B; Lye DCB; Tan KB
    Clin Microbiol Infect; 2024 Apr; 30(4):531-539. PubMed ID: 38141822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination.
    Varea-Jiménez E; Aznar Cano E; Vega-Piris L; Martínez Sánchez EV; Mazagatos C; García San Miguel Rodríguez-Alarcón L; Casas I; Sierra Moros MJ; Iglesias-Caballero M; Vazquez-Morón S; Larrauri A; Monge S;
    Enferm Infecc Microbiol Clin (Engl Ed); 2024 Apr; 42(4):187-194. PubMed ID: 36737369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and impact of persistent symptoms following SARS-CoV-2 infection among healthcare workers: A cross-sectional survey in the SIREN cohort.
    Foulkes S; Evans J; Neill C; Bishop J; Khawam J; Islam J; Atti A; Brown CS; Hopkins S; Price L; Hall V;
    J Infect; 2024 Oct; 89(4):106259. PubMed ID: 39214242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine Effect on Household Transmission of Omicron and Delta SARS-CoV-2 Variants.
    Kim YC; Kim B; Son NH; Heo N; Nam Y; Shin A; Yang AJ; Kim MH; Kyong T; Kang E; Park YS; Kim H
    J Korean Med Sci; 2023 Jan; 38(1):e9. PubMed ID: 36593690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2.
    Ward T; Glaser A; Overton CE; Carpenter B; Gent N; Seale AC
    Epidemiol Infect; 2022 Dec; 151():e32. PubMed ID: 36535802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.